Status:
UNKNOWN
Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients With Acute Respiratory Distress Syndrome
Lead Sponsor:
Guy's and St Thomas' NHS Foundation Trust
Collaborating Sponsors:
Australian and New Zealand Intensive Care Research Centre
Monash University
Conditions:
COVID
Acute Respiratory Distress Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to find out whether the use of angiotensin II, which is a drug to raise blood pressure has been approved by European Medical Agency in August 2019, as an add-on medication to increase ...
Detailed Description
COVID-19 is a rapidly evolving pandemic with approximately 5% of all patients requiring admission to the intensive care unit. In critically ill patients infected with COVID-19, ARDS is found in 40%, m...
Eligibility Criteria
Inclusion
- Adult patients (≥ 18 years old) admitted to intensive care units overseen by critical care consultants
- Confirmed COVID-19 infection
- ARDS defined as per the BERLIN ARDS definition1
- For angiotensin data only: Vasodilatory shock as diagnosed clinically by the treating physicians and receiving noradrenaline for less than 12 hours from the onset of shock or arrival to hospital
Exclusion
- Pure cardiogenic shock
- Stage 4 cancer
Key Trial Info
Start Date :
June 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04408326
Start Date
June 1 2020
End Date
December 31 2022
Last Update
August 4 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guy's & St Thomas' Hospital
London, United Kingdom, SE1 7EH